DCC2934 |
Boc-phe-leu-glup(oph) |
0 |
|
DCC2935 |
Km05382 |
CDK9 inhibitor, inhibiting transcription of GAPDH |
|
DCC2936 |
km10340 |
Selective S1P3 agonist |
|
DCC2937 |
Km-5-25 |
Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
DCC2938 |
Km-5-66 |
Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
DCC2939 |
kmi-1764 |
Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position |
|
DCC2940 |
Kmn-010034 |
Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor |
|
DCC2941 |
Kmn-80 |
Novel Potent and Selective EP4 Agonist |
|
DCC2942 |
kms80013 |
Novel inhibitor of amyloid- |
|
DCC2943 |
Kms88009 |
Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder |
|
DCC2944 |
Kmup-3 |
Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
DCC2945 |
Kmup-4 |
Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
DCC2946 |
Kongensin D |
Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects |
|
DCC2947 |
kp1212 |
Novel non-chain terminating nucleoside analog anti-HIV inhibitor |
|
DCC2948 |
Kpt-6604 |
Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer |
|
DCC2949 |
Kpu-300 |
Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn. |
|
DCC2950 |
Kr-12-a4 |
Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity |
|
DCC2951 |
Kr-25210 |
Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus |
|
DCC2952 |
Kr-31762 |
Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury |
|
DCC2953 |
Kras(g12c)-in-1 |
Novel irreversible inhibitor of KRAS(G12C) |
|
DCC2954 |
Kras4b-in-d14 |
Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells |
|
DCC2955 |
Kras4b-pdeδ Stabilizer C19 |
Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling |
|
DCC2956 |
Krc-108 |
Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met |
|
DCC2957 |
Krc-327 |
Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. |
|
DCC2958 |
Krm-ii-08 |
Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c |
|
DCC2959 |
Krn4884 |
Potassium channel opener |
|
DCC2960 |
Krn-8602 Hydrochloride |
Topo II inhibitor, exhibiting cytotoxic effects against tumour cells |
|
DCC2961 |
Krp-109 |
Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes |
|
DCC2962 |
Krp-199 |
Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo |
|
DCC2963 |
Krp-204 |
Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity |
|